FDA declines to approve novel infusion for uncontrolled gout over manufacturing concerns

The FDA has declined to approve Sobi’s investigational infusion of nanoencapsulated sirolimus plus pegadricase for adults with uncontrolled gout, according to a press release from the manufacturer.The FDA issued a complete response letter to Sobi requiring additional information regarding manufacturing control strategy of the biological component of the drug, as well as to address contract